These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 22483497

  • 41. Optimizing outcome of recurrent hepatitis C virus genotype 4 after living donor liver transplantation: moving forward by looking back.
    Dabbous HM, Elmeteini MS, Sakr MA, Montasser IF, Bahaa M, Abdelaal A, Fathy M, Refaie R, Seyam M, Abdelmonem A, Mukhtar A, Hegazy N, Almoneiri M.
    Transplant Proc; 2014 Apr; 46(3):822-7. PubMed ID: 24767357
    [Abstract] [Full Text] [Related]

  • 42. rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C: a case report.
    Yoshida Y, Ikegami T, Yoshizumi T, Toshima T, Yamashita YI, Yoshiya S, Shirabe K, Maehara Y.
    Transplant Proc; 2014 Sep; 46(7):2426-9. PubMed ID: 25150603
    [Abstract] [Full Text] [Related]

  • 43. Current and future HCV therapy: do we still need other anti-HCV drugs?
    Petta S, Craxì A.
    Liver Int; 2015 Jan; 35 Suppl 1():4-10. PubMed ID: 25529081
    [Abstract] [Full Text] [Related]

  • 44. Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: a re-examination of the situation.
    Willuweit K, Canbay A, Gerken G, Timm J, Paul A, Treckmann J, Herzer K.
    Minerva Gastroenterol Dietol; 2017 Mar; 63(1):55-61. PubMed ID: 27824245
    [Abstract] [Full Text] [Related]

  • 45. Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy.
    Alhamlan FS, Al-Ahdal MN, Khalaf NZ, Abdo AA, Sanai FM, Al-Ashgar HI, ElHefnawi M, Zaid A, Al-Qahtani AA.
    J Transl Med; 2014 Apr 06; 12():91. PubMed ID: 24708767
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Successful laparoscopic splenectomy after living-donor liver transplantation for thrombocytopenia caused by antiviral therapy.
    Kato H, Usui M, Azumi Y, Ohsawa I, Kishiwada M, Sakurai H, Tabata M, Isaji S.
    World J Gastroenterol; 2008 Jul 14; 14(26):4245-8. PubMed ID: 18636675
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Living donor liver transplantation to patients with hepatitis C virus cirrhosis.
    Sugawara Y, Makuuchi M.
    World J Gastroenterol; 2006 Jul 28; 12(28):4461-5. PubMed ID: 16874855
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy.
    Ramadori G, Bosio P, Moriconi F, Malik IA.
    BMC Cancer; 2018 Mar 06; 18(1):257. PubMed ID: 29510685
    [Abstract] [Full Text] [Related]

  • 55. Infection fighters. Hepatitis C--is a cure possible?
    TreatmentUpdate; 2005 Mar 06; 17(1):8-9. PubMed ID: 17225319
    [No Abstract] [Full Text] [Related]

  • 56. Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation.
    Kim H, Lee KW, Yi NJ, Lee HW, Choi Y, Suh SW, Jeong J, Suh KS.
    J Korean Med Sci; 2015 Nov 06; 30(11):1577-83. PubMed ID: 26539000
    [Abstract] [Full Text] [Related]

  • 57. New modalities in the treatment of HCV in pre and post - transplantation setting.
    Araz F, Durand CM, Gürakar A.
    Turk J Gastroenterol; 2015 May 06; 26(3):204-13. PubMed ID: 26006192
    [Abstract] [Full Text] [Related]

  • 58. Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver-kidney transplant recipients.
    Nookala AU, Crismale J, Schiano T, Te H, Ahn J, Robertazzi S, Rodigas C, Satoskar R, Kc M, Hassan M, Smith C.
    Clin Transplant; 2018 Mar 06; 32(3):e13198. PubMed ID: 29323755
    [Abstract] [Full Text] [Related]

  • 59. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
    Mori K, Hiraoka O, Ikeda M, Ariumi Y, Hiramoto A, Wataya Y, Kato N.
    Hepatology; 2013 Oct 06; 58(4):1236-44. PubMed ID: 23532970
    [Abstract] [Full Text] [Related]

  • 60. Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C-positive recipients.
    Martini S, Tandoi F, Terzi di Bergamo L, Strona S, Lavezzo B, Sacco M, Maione F, Gonella F, Strignano P, Dell Olio D, Salizzoni M, Saracco GM, Romagnoli R.
    Liver Transpl; 2017 Jul 06; 23(7):915-924. PubMed ID: 28422425
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.